Skip to content
Menu

RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $7

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $7.

RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $7.

Read at benzinga.com